Sign up
PALI

Palisade Bio Inc (NASDAQ: PALI)

Healthcare · Biotechnology

$0.94−0.07 (−6.93%)

Last close · Nov 18, 2026 · NASDAQ USD

Set alert

The Quantellect read. PALI fell 6.93% in the Nov 18 session to $0.94, which is 66.4% below its 52-week high of $2.80. Eight active firms cover the stock as of Nov 19, 2026; eight active firms with targets average $9.63 over 12 months. Descriptive summary of the data on this page, not a recommendation.

Relative valuation—

—

MomentumNeutral

RSI (14) 39.8 (overbought above 70, oversold below 30)

Trend—

—

Short interest—

—

PALI price chart

Price $0.94 · As of Nov 18, 2026, 3:59 PM ET

Open full chart →
Price details unavailable for this range.

Chart loads when this section enters view.

Text price and event history
6M plotted price range (ET)
Range6M
First date—
Last date—
Open—
High—
Low—
Close—
Volume—
Plotted bars0

Plotted OHLCV bars

No price bars are available for this range.

Event records

Event records load after the price chart.

Split-adjusted daily prices · Price as of —

Initial 6M price range summary
Range6M
First close—
Last close—
High—
Low—
Volume—
Open
$1.00Nov 18, 2026 session
Previous close
$1.01Nov 17, 2026 close
Day range
$0.94 – $1.01Nov 18, 2026 session
52-week range
$0.94 – $2.80Through Nov 18, 2026
Volume
5.45MNov 18, 2026 session
Average volume (30 calendar days, 0 sessions)
—Through Nov 18, 2026
Market cap$202.15M
P/E (TTM)1.2
Forward P/E—
EPS (TTM)stale vendor snapshot —
Dividend yielddata unavailable —
Beta (5-year monthly vs SPY)—

Price history

PALI · NASDAQ · USD

Split-adjusted · volume in shares

Price history unavailable

Notable price movement

— · Notable price movement not available

Options flow

— · Options flow not available

Q Score

— · Q Score not available

Quantellect signals

Change since Nov 18
Squeeze37Watch—
How the scores work →

Industry comparison

— · Industry comparison not available

Upcoming events

— · Upcoming events not available

Analyst consensus

Buy

0Strong Buy
8Buy
0Neutral
0Sell
0Strong Sell

Based on 8 active firms as of Nov 19, 2026 (365-day activity window)

12-month price targets (third-party analysts)

Low$5.00
Average$9.63
High$25.00

As of Nov 19, 2026 across 8 active firms with targets. Targets are published by third-party analysts, not by Quantellect.

Full analyst forecast →

Earnings history

EPS, last 8 quarters
EstimateBeatMissMatch
Fiscal periodEst.ActualResult
Q3 2026−$0.06−$0.07—
Q2 2026−$0.05−$0.05—
Q1 2026−$0.04−$0.05—
Annual 2025−$0.03−$0.30—
Q3 2025—−$0.38—
Q2 2025—−$0.58—
Q1 2025—−$0.47—
Annual 2024−$1.99−$10.19—

Smart-money activity

— · Smart-money activity not available

All smart-money activity →

News and press releases

News and press releases are not available.

All PALI news →

Company profile

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, engages in developing oral phosphodiesterase-4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon in the United States. Its lead clinical product candidate includes PALI-2108, which is in phase 1b clinical trial to treat patients with inflammatory bowel disease, including ulcerative colitis and Fibrostenotic Crohn's disease. The company has a research collaboration and license agreement with Giiant

CEO
Mr. J. D. Finley
Headquarters
Denver, CO, United States
Employees
14
IPO date
Dec 20, 2006
Sector
Healthcare
Industry
Biotechnology

Data sources: exchange quotes delayed 15 minutes, FINRA short interest, SEC filings, OPRA options data and third-party analyst data. Education only. Nothing on this page is a recommendation to buy or sell a security.